# Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C

Source: https://onco.cc/trials/nct07680790/  
OnCo record `nct07680790` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of izalontamab brengitecan, osimertinib, pemetrexed, carboplatin and other drugs in lung cancer, run by Bristol-Myers Squibb, not yet recruiting.

## Summary

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) is a phase 3, randomised interventional study registered as NCT07680790 by Bristol-Myers Squibb, with a registry enrolment figure of 850 participants, started 2026-09-30 and due to reach its primary completion in 2031-12-30. Interventions recorded: Iza-bren; Osimertinib; Pemetrexed; Carboplatin; Cisplatin. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Lung eligibility wording from the registry: "* Participants must have histologically or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), metastatic (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatment". Sites: Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, South Korea, Spain and 4 more countries. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07680790
- Phase: 3
- Setting: A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Sponsor: Bristol-Myers Squibb
- Enrolled: 850

## Sources

- ClinicalTrials.gov NCT07680790: https://clinicaltrials.gov/study/NCT07680790

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07680790.json